Skip to main content
Laurus Labs Limited logo

Laurus Labs Limited — Investor Relations & Filings

Ticker · LAURUSLABS ISIN · INE947Q01028 LEI · 335800S8HO8QRYP3VQ26 BSE.NS Manufacturing
Open in API
Filings indexed 707 across all filing types
Latest filing 2021-04-29 Earnings Release
Country IN India
Listing BSE.NS LAURUSLABS

About Laurus Labs Limited

https://www.lauruslabs.com/

Laurus Labs Limited is a research-driven organization focused on the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms (FDF), and specialized synthesis services. The company operates across several key therapeutic areas, including anti-retroviral (ARV), oncology, cardiovascular, and anti-diabetic treatments. Through its contract development and manufacturing organization (CDMO) division, it provides integrated drug development solutions to global partners. The company also maintains a biotechnology segment dedicated to recombinant products. Leveraging advanced research and development capabilities alongside large-scale manufacturing infrastructure, the firm emphasizes process chemistry innovation and cost-efficient production to serve diverse global healthcare markets.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated April 29, 2021, announcing the Q4 and full fiscal year 2021 financial results of Laurus Labs Limited. It contains detailed financial performance data including revenues, EBITDA, PAT, EPS, and business highlights for the fiscal year 2021. The document includes commentary from the CEO and CFO on the financial results and business outlook. The content is typical of an Earnings Release (ER) as it provides key financial highlights and summary results for a quarterly and annual period but does not contain the full detailed financial statements or comprehensive management discussion found in an Annual Report (10-K) or Interim Report (IR). The length of the document (7742 characters) and the detailed financial figures support classification as an Earnings Release rather than a brief announcement or a full report. Therefore, the appropriate classification is Earnings Release (ER). FY 2021
2021-04-29 English
Outcome of Board Meeting
Regulatory Filings
2021-04-29 English
Financial Result Updates
Interim / Quarterly Report Classification · 95% confidence The document is a detailed financial statement from Laurus Labs Limited, including audited standalone and consolidated financial results for the year ended March 31, 2021, and limited reviewed financial results for the quarter ended March 31, 2021. It references Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and includes comprehensive financial data such as income, expenses, profit before tax, tax expense, net profit, other comprehensive income, earnings per share, and balance sheet items. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. It contains actual financial statements and analysis, not just a notification or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR) because it includes quarterly and annual financial results with substantive financial data and analysis, but it is not a full annual report (10-K). FY 2021
2021-04-29 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 85% confidence The document is an announcement of a conference call scheduled for April 30, 2021, to discuss Q4 and FY21 results of Laurus Labs Ltd. It includes details for joining the call and a brief company description. There are no actual financial statements or detailed financial analysis present in the text. The document is short (2384 characters) and serves as an invitation and information about the call rather than the call transcript itself. Therefore, it is not a full Call Transcript (CT) but rather an announcement related to the call. However, since there is no specific category for call announcements, the closest appropriate classification is Call Transcript (CT) because the document is directly related to the earnings call event and is not a report publication announcement or regulatory filing. Confidence is high due to clear identification of the document as a conference call announcement for earnings results.
2021-04-26 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document text is extremely short (59 characters) and contains no substantive content, only a placeholder for an omitted picture. There is no financial data, report content, or any announcement text. Given the lack of content, this cannot be classified as a report or detailed filing. It fits best as a Regulatory Filing (RNS) as a fallback category for miscellaneous or non-informative filings.
2021-04-22 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings
2021-04-08 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.